128 related articles for article (PubMed ID: 22771631)
1. N-O-isopropyl sulfonamido-based hydroxamates: kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors.
Santamaria S; Nuti E; Cercignani G; Marinelli L; La Pietra V; Novellino E; Rossello A
Biochem Pharmacol; 2012 Sep; 84(6):813-20. PubMed ID: 22771631
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
[TBL] [Abstract][Full Text] [Related]
3. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
4. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
[TBL] [Abstract][Full Text] [Related]
5. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
[TBL] [Abstract][Full Text] [Related]
6. MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.
Barta TE; Becker DP; Bedell LJ; Easton AM; Hockerman SL; Kiefer J; Munie GE; Mathis KJ; Li MH; Rico JG; Villamil CI; Williams JM
Bioorg Med Chem Lett; 2011 May; 21(10):2820-2. PubMed ID: 21507637
[TBL] [Abstract][Full Text] [Related]
7. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
[TBL] [Abstract][Full Text] [Related]
8. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
9. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
[TBL] [Abstract][Full Text] [Related]
12. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
14. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
15. Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases.
Bertini I; Calderone V; Fragai M; Giachetti A; Loconte M; Luchinat C; Maletta M; Nativi C; Yeo KJ
J Am Chem Soc; 2007 Mar; 129(9):2466-75. PubMed ID: 17269766
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.
Nuti E; Panelli L; Casalini F; Avramova SI; Orlandini E; Santamaria S; Nencetti S; Tuccinardi T; Martinelli A; Cercignani G; D'Amelio N; Maiocchi A; Uggeri F; Rossello A
J Med Chem; 2009 Oct; 52(20):6347-61. PubMed ID: 19775099
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
[TBL] [Abstract][Full Text] [Related]
18. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
[TBL] [Abstract][Full Text] [Related]
19. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.
Pochetti G; Gavuzzo E; Campestre C; Agamennone M; Tortorella P; Consalvi V; Gallina C; Hiller O; Tschesche H; Tucker PA; Mazza F
J Med Chem; 2006 Feb; 49(3):923-31. PubMed ID: 16451058
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
